St. Jude co-corresponding authors Caitlin Zebley, MD, PhD, Department of Bone Marrow Transplantation & Cellular Therapy and Ben Youngblood, PhD, Department of Immunology, used an epigenetic clock to show that T cells can outlive their organism by at least four lifespans and that T cell acute lymphoblastic leukemia hyperproliferation results in cells which appear hundreds of years old.
While most cell types experience a functional decline after years of proliferation and replication, T cells can proliferate seemingly indefinitely and without detriment. Scientists at St. Jude Children’s Research Hospital and the University of Minnesota investigated the unique ‘epigenetic clock’ of T-cell aging, demonstrating that T cells can outlive an organism through at least four lifetimes. In addition, the researchers showed that healthy T cell age was uncoupled from the organism’s chronologic age. Furthermore, they determined that malignant T cells from pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) appeared to have aged up to 200 years. The findings were published today in Nature Aging.
As researchers explore the process of cellular aging through repeat replicative cycles of growth, some peculiar patterns have emerged regarding T cells. “The immune system by nature must mount a rapid proliferative response to a pathogen or a tumor,” said co-corresponding author Ben Youngblood, PhD, St. Jude Department of Immunology. “And in some settings, such as endemic pathogens or chronic viral infections, this happens over and over again. That's a lot of proliferation that these T cells undergo in the lifespan of a human.” This raised the question as to why, despite these accelerated rates of proliferation, this immune response doesn’t trigger cancer development.
The answer lies in a T cell’s unique ability to defy aging.
Epigenetic markers offer more accurate metrics for age
To study this phenomenon, the researchers made use of specific biomarkers known as epigenetic markers that accumulate over time. Like counting the rings on a tree stump in a forest, this ‘epigenetic clock’ tells a retrospective story about the life cycle of a cell independent of the organism itself. The accumulation of genetic mutations, the shortening of telomeres (the protective caps on chromosomes) and methylation patterns are currently regarded as the most accurate ways to interrogate the process of aging.
The researchers saw this as an ideal way to investigate the curious case of T-cell aging. “We started asking questions about what the hallmarks of aging are, specifically the epigenetic hallmarks, and how these can be applied to long-lived T cells,” he said. “One of the big questions we had was whether these epigenetic clocks are bound by the lifespan of the organism or not.”
Model shows T cells can outlive their origin organism
Through a collaboration with co-corresponding author David Masopust, PhD, University of Minnesota, the researchers found the perfect model to address their questions. This model used the same line of T cells through several mouse life cycles. “Dr. Masopust started this model assuming the cells would eventually decline, but they didn't, they just kept going,” explains Youngblood. “This led to his foundational 10-year mouse study which we subsequently used to address whether organismal lifespan limits constrain epigenetic clocks.”
Using this model and an epigenetic clock they developed for T cells, the researchers explored the DNA methylation patterns of T-cell lineage. They found that age is just a number, and death is not the end. “Humans don't live forever. But in this case, we could test that concept for T cells,” Youngblood said. “Is there an end to an epigenetic clock? Does it plateau? And it didn't for up to four lifetimes, it just kept counting, which was incredible. These cells are not bound by the reasonable limits of organism lifespan.”
Cancerous T cells appear hundreds of years old
Next, the researchers determined what happened under conditions of rapid and prolonged proliferation such as in cancer. The team interrogated the T cells of patients with pediatric T-ALL to investigate what happens to their epigenetic clock. “If epigenetic clocks were linked to the host’s chronologic age, then you would expect the T cells from pediatric T-ALL patients to appear young in age,” said co-corresponding author Caitlin Zebley, MD, PhD, St. Jude Department of Bone Marrow Transplantation & Cellular Therapy. “But our clock predicted these cells to be very old.”
From an experiential perspective, the T cells of T-ALL patients appeared to range from 100 to 200 years old. “We think this was related to the fact that they were proliferating so rapidly,” Zebley concluded. The T-ALL model offered invaluable insight into the aging process of leukemia cells. “We were able to use this as a subtraction model from all other programs in leukemia to identify ones that are associated with normal aging and proliferation versus ones that are distinct to leukemia,” Youngblood said. “We gained a better idea of which epigenetic programs are associated with leukemia and which are just normal hyperproliferation and aging.”
T-cell survival is vital to our survival
Considering how active our immune system is, T-cell survival is vital to our overall survival. “T-cells have so many opportunities to turn cancerous,” Youngblood said, “But they can't, otherwise humanity wouldn't exist.”
Youngblood, Zebley and Masopust are continuing to study the checks and balances that prevent T cells from undergoing malignant transformation. Through this work, potential therapies that halt, or even reverse, age-related impairments can begin to be considered.
Authors and funding
The study’s first author is Tian Mi, St. Jude. The study’s other authors are Shanta Alli, Tae Gun Kang, Anoop Babu Vasandan, Zhaoming Wang, Ilaria Iacobucci and Charles Mullighan, St. Jude; Andrew Soerens and Vaiva Vezys, University of Minnesota; Stephen Baylin, The Sidney Kimmel Comprehensive Cancer Institute at Johns Hopkins; Peter Jones, Van Andel Institute; and Christopher Hiner, April Mueller, and Harris Goldstein, Albert Einstein College of Medicine.
The study was supported by grants from the National Institutes of Health (R01AI114442, R01CA237311, U01AI144616, R01AI084913, R01AI146032, R01CA238439, R01AI172607, R01AI145024, K08CA279926), the National Comprehensive Cancer Network, Alex’s Lemonade Stand Foundation, Stand Up to Cancer, the ASSISI Foundation, the Key for a Cure Foundation and ALSAC, the fundraising and awareness organization of St. Jude.
If you are interested in licensing the T-cell aging biomarker from St. Jude (SJ-23-0009) for further development and/or commercial use, find out more about licensing.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease, and other life-threatening disorders. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. To learn more, visit stjude.org, read St. Jude Progress, a digital magazine, and follow St. Jude on social media at @stjuderesearch.